Kiniksa Pharmaceuticals International PLC

KNSA

Healthcare|Drug Manufacturers - Specialty & Generic|UK

$63.44

-1.91 (-2.92%)

DCF (FCF)

$4.91

Tangible Book

$7.70

Graham Number

$12.49

Clinical Trials (10)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT07010159 Phase 2/3 Study of KPL-387 in Recurrent Pericarditis	Pericarditis, Pericarditis Acute	P2P3	Recruiting	165	RCT, Double-blind	KPL-387, Placebo
NCT07288216 Transition to KPL-387 Monotherapy Dosing & Administration Study	Recurrent Pericarditis, Heart Diseases	P2	Recruiting	80	Open-label	KPL-387
NCT04687358 REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients	Recurrent Pericarditis		Active	500	—	—
NCT03737110 Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis	Recurrent Pericarditis	P3	Completed	86	RCT, Double-blind	Rilonacept, Placebo
NCT04447469 Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation	COVID	P2P3	Completed	814	RCT, Double-blind	mavrilimumab
NCT05198310 Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor	Arthritis, Rheumatoid	P2	Completed	145	RCT, Double-blind	KPL-404, Placebo
NCT03980522 A Pilot Study of KPL-914 in Recurrent Pericarditis	Recurrent Pericarditis	P2	Completed	26	Open-label	KPL-914
NCT06531395 A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease	Sjögrens Disease	P2	Terminated	3	RCT, Double-blind	Abiprubart, Placebo
NCT03827018 KPL-301 for Subjects With Giant Cell Arteritis	Giant Cell Arteritis	P2	Completed	70	RCT, Double-blind	prednisone
NCT04497662 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects	Healthy Volunteers	P1	Completed	52	RCT, Double-blind	KPL-404